RARγ Selective Ligand Design for Reduced Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds for modulating retinoic acid receptors (RAR) lack specificity and efficacy in treating various dermatological and cellular disorders, with existing ligands often having broad receptor activation that can lead to undesirable side effects.
Innovation Solution
Development of novel ligand compounds with specific modulatory properties on RARα, β, and γ receptors, characterized by specific structural formulas and salts, which are designed to selectively activate RARγ receptors with improved dissociation constants, allowing for targeted therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing RAR ligands are used to treat dermatological disorders, then broad receptor activation occurs, but this leads to undesirable side effects due to lack of specificity
Solution Approach 1:
The patent applies local quality by designing ligands with specific molecular structures (formula I) that selectively bind to RARγ receptors rather than activating all RAR subtypes uniformly. The compounds feature specific substituents at defined positions (R1-R7, n) that confer selectivity for RARγ over RARα and RARβ, thereby targeting the therapeutic action to a specific receptor subtype to reduce off-target side effects
Solution Approach 2:
The patent employs parameter changes by optimizing the dissociation constant (Kd) values for RARγ receptors to achieve enhanced binding affinity and selectivity. The ligands are designed with specific structural parameters (substituent types, positions, and configurations) that modulate the binding characteristics to preferentially interact with RARγ, thereby improving therapeutic reliability while minimizing harmful effects from broad activation
2Reliability
If existing RAR ligands are used, then receptor activation occurs, but specificity is lacking leading to broad activation patterns
Solution Approach 1:
The patent implements local quality by introducing specific structural features at defined positions in the ligand molecule (formula I) that create selective interaction with RARγ receptors. The substituents R1-R7 and parameter n are carefully selected to provide local molecular characteristics that match the binding pocket of RARγ, enabling precise receptor targeting rather than broad activation
Solution Approach 2:
The patent applies asymmetry by designing ligands with non-uniform substituent patterns around the core structure. The asymmetric arrangement of R1-R7 groups and the specific configuration at different positions create a chiral or geometric asymmetry that allows selective fitting into the RARγ binding site, thereby achieving high receptor specificity through asymmetric molecular design
Data Source
AI summary
Novel ligand compounds having the general formula (I):and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.